Effect Of Zoledronic Acid On Bone Metabolism In Endocrine Therapy Of Patients With Advanced Prostate Cancer

Objective:To investigate the effects of zoledronic acid on the levels of bone metabolism related markers in endocrine therapy in patients with advanced prostate cancer,and to explore the role of this drug in indicators related to bone metabolism,including bone mineral density(BMD),serum calcium ions,blood.Phosphorus and serum alkaline phosphatase(ALP),etc.,provide a rational medication guide for bone loss in endocrine therapy in patients with advanced PCa.Methods:This study collected patients with advanced prostate cancer who were treated in the outpatient department and inpatient department from October 2016 to October2018 in our hospital.From the stage and grade of prostate cancer,the history of previous malignant tumors,and the presence or absence of heart and liver Screening for incomplete function,with or without radiotherapy and chemotherapy history.Forty patients who met the inclusion criteria were randomly assigned to the observation group and the control group,with 20 patients in each group.Patients receiving zoledronic acid combined with endocrine therapy were included in the observation group,and patients receiving endocrine therapy alone were included in the control group.The pre-treatment age,body mass index(BMI),Gleason score,creatinine,BMD,serum calcium ion,serum phosphorus,ALP,PSA,and BMD,serum calcium,blood phosphorus,ALP,and6 months after treatment were recorded.PSA and adverse events.The resulting data was statistically analyzed.Results:The study included a total of 40 patients,aged 55 to 83 years,with statistical analysis of relevant clinical data for these patients.There were no significant differences between the observation group and the control group in pre-treatment age,body mass index(BMI),Gleason score,creatinine,BMD,serum calcium ion,serum phosphorus,ALP,PSA(P>0.05).After 6 months of treatment in the two groups,BMD was(1.13±0.03)g/cm~2 in the observation group and(1.08±0.02)g/cm~2 in the control group after treatment.After statistical analysis,The difference in this aspect was statistically significant(P<0.05).In the case of blood calcium,the blood calcium in the observation group was(2.44±0.13)mmol/L,and the blood calcium in the control group was(2.62±0.10)mmol/L,after statistical analysis,the difference in this aspect was statistically significant(P<0.05);in the blood phosphorus,the level of the observation group was(1.18±0.06)mmol/L after treatment,and the level of the control group after treatment For(1.34±0.04)mmol/L,the difference in this aspect was statistically significant(P<0.05).In the ALP,the ALP was(190.79±75.27)U/L in the observation group after treatment.After treatment,ALP was(359.36±87.79)U/L.The difference in ALP contrast was statistically significant(P<0.05).In PSA,the PSA after treatment was(3.56±0.65)ng/ml,PSA was(3.25±0.66)ng/ml after treatment in the control group,and the difference in PSA after statistical analysis was not statistically significant.Meaning(P>0.05).In terms of flu-like symptoms,fever,gastrointestinal disorders and hypocalcemia and other related adverse events,statistical analysis showed that there was no statistically significant difference between the observation group and the control group in terms of adverse events(P>0.05).Conclusion:Zoledronic acid as a new generation bisphosphonate,used in endocrine therapy in patients with advanced PCa(4mg,intravenous drip,once a month),can reduce blood calcium,blood phosphorus,ALP and other indicators,improve bone density,thereby reducing bone loss during endocrine therapy.It has a certain significance for improving patients’quality of life and survival rate,and patients are generally well tolerated and worthy of clinical promotion.